Developer docs
API playgroundTry for free, no card

Search company profiles

Fibrocell Science Inc

Full company profile

uuid00pxpfe

Namestring
Fibrocell Science Inc
Websiteurl
fibrocell.com
Company typeenum
Private
Founded yearint
1995
Descriptiontext

Fibrocell Science Inc is a private, for-profit biotechnology company founded in 1995 and headquartered in Exton, Pennsylvania. According to the firmographic description provided, the company develops autologous cell and gene therapies targeted at diseases of the skin and connective tissue. Its therapeutic approach is autologous, meaning treatments are derived from a patient's own cells, placing the company within the personalized regenerative medicine segment of the biotech industry.

The company's product offering, specific pipeline assets, clinical development stage, manufacturing approach, and underlying technical platform were not disclosed in the source material. As a private entity operating in a regulated biologics category, its economics would typically be driven by long-cycle R&D investment, clinical milestones, and potential partnerships or licensing with larger pharmaceutical companies; however, no funding history, capitalization, partnership agreements, or commercialization signals were available. The source data also contained substantial unrelated content about an unrelated gambling website and a t-shirt marketplace, which carries no information about the company.

No information was provided on headcount, revenue, ownership structure, operating status, customer segments, distribution channels, or recent strategic actions. Any analytical conclusions beyond the company's stated therapeutic focus, founding year, and location should be treated as unsupported by the available data.

Short descriptiontext

Fibrocell Science Inc is a private biotechnology company founded in 1995 in Exton, Pennsylvania that develops autologous cell and gene therapies for diseases of the skin and connective tissue.

Ownership categoryenum
akta.pro rankint
HeadquartersExton, United States
HQ citystring
Exton
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
autologous cell therapy, gene therapy, regenerative medicine, dermatology therapeutics, connective tissue therapy
Industry2 codes
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Cell and Gene Therapy
Social media profiles1 record
Cost components4 values
Technology or R&D, Personnel, Operations, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Fibrocell Science develops autologous cell and gene therapies intended for the treatment of diseases of the skin and connective tissue. The company's product work is centered on patient-derived (autologous) cellular and gene-based therapeutic candidates aimed at dermatological and connective-tissue indications.

Differentiator
Functional benefit
Problem solved
No data
Peers8 records
1Castle Creek Biosciences
TypeDirect peer
Description

Develops autologous cell and gene therapies for recessive dystrophic epidermolysis bullosa and other skin/connective tissue diseases — directly overlapping Fibrocell's therapeutic focus and autologous modality.

2Krystal Biotech
TypeDirect peer
Description

Commercial-stage gene therapy company focused on skin diseases (e.g., Vyjuvek for dystrophic EB); directly comparable therapeutic area and connective tissue modality to Fibrocell.

3Abeona Therapeutics
TypeDirect peer
Description

Clinical-stage cell and gene therapy developer with EB and skin-focused programs; shares Fibrocell's autologous gene-therapy approach and rare dermatology focus.

4Vericel
TypeDirect peer
Description

Commercial autologous cell therapy company (MACI for cartilage repair, Epicel for burns); shares the autologous manufacturing platform and skin/connective tissue adjacency.

5Organogenesis
TypeBroad incumbent
Description

Established regenerative medicine company in wound care and skin/connective tissue repair; broader portfolio than Fibrocell but operates in overlapping tissue regeneration categories.

6AIVITA Biomedical
TypeEmerging player
Description

Clinical-stage cell therapy developer with autologous dendritic cell and skin/wound programs; comparable autologous modality and emerging commercial stage.

7StemBioCell
TypeEmerging player
Description

Early-stage autologous cell therapy developer focused on skin and connective tissue indications; overlaps with Fibrocell's niche and modality.

8RHEACELL
TypeEmerging player
Description

Clinical-stage developer of cell-based therapies for wound healing and skin regeneration; comparable autologous cell therapy modality and dermatology focus.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Fibrocell Science Inc

Cell and Gene Therapyfibrocell.com

Fibrocell Science Inc is a private biotechnology company founded in 1995 in Exton, Pennsylvania that develops autologous cell and gene therapies for diseases of the skin and connective tissue.

What Fibrocell Science Inc does

Fibrocell Science Inc is a private, for-profit biotechnology company founded in 1995 and headquartered in Exton, Pennsylvania. According to the firmographic description provided, the company develops autologous cell and gene therapies targeted at diseases of the skin and connective tissue. Its therapeutic approach is autologous, meaning treatments are derived from a patient's own cells, placing the company within the personalized regenerative medicine segment of the biotech industry.

The company's product offering, specific pipeline assets, clinical development stage, manufacturing approach, and underlying technical platform were not disclosed in the source material. As a private entity operating in a regulated biologics category, its economics would typically be driven by long-cycle R&D investment, clinical milestones, and potential partnerships or licensing with larger pharmaceutical companies; however, no funding history, capitalization, partnership agreements, or commercialization signals were available. The source data also contained substantial unrelated content about an unrelated gambling website and a t-shirt marketplace, which carries no information about the company.

No information was provided on headcount, revenue, ownership structure, operating status, customer segments, distribution channels, or recent strategic actions. Any analytical conclusions beyond the company's stated therapeutic focus, founding year, and location should be treated as unsupported by the available data.

Fibrocell Science Inc firmographics

Firmographics
Name
Fibrocell Science Inc
Website
https://fibrocell.com
Company type
Private
Founded year
1995
Short description
Fibrocell Science Inc is a private biotechnology company founded in 1995 in Exton, Pennsylvania that develops autologous cell and gene therapies for diseases of the skin and connective tissue.
Ownership category
akta.pro rank

Fibrocell Science Inc industry classification

Industry
Product category
Cell and Gene Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAABAA
Cell Therapy Developers (Autologous)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Autologous cell therapy
  • Gene therapy
  • Regenerative medicine
  • Dermatology therapeutics
  • Connective tissue therapy

Where Fibrocell Science Inc is headquartered

Location

Headquarters

HQ city
Exton
HQ country
United States
HQ region
North America

Markets served

Fibrocell Science Inc business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Supply Chain

Fibrocell Science Inc product offering

Product offering

Core offering

Fibrocell Science develops autologous cell and gene therapies intended for the treatment of diseases of the skin and connective tissue. The company's product work is centered on patient-derived (autologous) cellular and gene-based therapeutic candidates aimed at dermatological and connective-tissue indications.

Differentiator

Problem solved

Functional benefit

Companies that use Fibrocell Science Inc

Customer profile

Ideal customer profiles1 record

Fibrocell Science Inc technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Fibrocell Science Inc competitors and assessment

Company assessment

Direct peers

  • Castle Creek Biosciences: Develops autologous cell and gene therapies for recessive dystrophic epidermolysis bullosa and other skin/connective tissue diseases — directly overlapping Fibrocell's therapeutic focus and autologous modality.
  • Krystal Biotech: Commercial-stage gene therapy company focused on skin diseases (e.g., Vyjuvek for dystrophic EB); directly comparable therapeutic area and connective tissue modality to Fibrocell.
  • Abeona Therapeutics: Clinical-stage cell and gene therapy developer with EB and skin-focused programs; shares Fibrocell's autologous gene-therapy approach and rare dermatology focus.
  • Vericel: Commercial autologous cell therapy company (MACI for cartilage repair, Epicel for burns); shares the autologous manufacturing platform and skin/connective tissue adjacency.

Broad incumbents

  • Organogenesis: Established regenerative medicine company in wound care and skin/connective tissue repair; broader portfolio than Fibrocell but operates in overlapping tissue regeneration categories.

Emerging players

  • AIVITA Biomedical: Clinical-stage cell therapy developer with autologous dendritic cell and skin/wound programs; comparable autologous modality and emerging commercial stage.
  • StemBioCell: Early-stage autologous cell therapy developer focused on skin and connective tissue indications; overlaps with Fibrocell's niche and modality.
  • RHEACELL: Clinical-stage developer of cell-based therapies for wound healing and skin regeneration; comparable autologous cell therapy modality and dermatology focus.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat3 records

Key risks4 records

Key highlights3 records

Customer concentration

Fibrocell Science Inc social profiles

Digital presence

Fibrocell Science Inc financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Fibrocell Science Inc leadership team

Management profile

Number of profiles

Fibrocell Science Inc funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Fibrocell Science Inc M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Fibrocell Science Inc

What does Fibrocell Science Inc do?

Fibrocell Science develops autologous cell and gene therapies intended for the treatment of diseases of the skin and connective tissue. The company's product work is centered on patient-derived (autologous) cellular and gene-based therapeutic candidates aimed at dermatological and connective-tissue indications.

When was Fibrocell Science Inc founded?

Fibrocell Science Inc was founded in 1995.

Where is Fibrocell Science Inc based?

Fibrocell Science Inc is headquartered in Exton, United States, in the North America region.

Who are Fibrocell Science Inc's main competitors?

Direct peers on record are Castle Creek Biosciences, Krystal Biotech, Abeona Therapeutics and Vericel. Organogenesis is listed as a broad incumbent. Emerging players are AIVITA Biomedical, StemBioCell and RHEACELL.

Does Fibrocell Science Inc have an API?

No public API is recorded for Fibrocell Science Inc.

What industry is Fibrocell Science Inc in?

Fibrocell Science Inc's product category is Cell and Gene Therapy. Its primary akta.pro industry code is HLAAABAA, Cell Therapy Developers (Autologous), with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGlobal Cell Therapy Markets, 2015-2020, 2020-2025F, 2030F: Stem Cell Therapy, Cell Vaccine, Adoptive Cell Transfer (ACT), Fibroblast Cell Therapy, Chondrocyte Cell TherapyResearch and Markets has published the 'Cell Therapy Global Market Report 2021', forecasting the global cell therapy market to grow from $7.2 billion in 2020 to $7.82 billion in 2021, with a projected reach of $12.06 billion by 2025. The report identifies key industry players such as Fibrocell Science Inc., JCR Pharmaceuticals Co. Ltd., and Bayer AG, noting that growth is driven by the rising prevalence of chronic diseases despite high treatment costs.PR NewswireInsights Into the $8.8 Billion Cell Therapy Industry, 2020-2027 - Rising Adoption of Regenerative Medicine, Introduction of Novel Platforms & TechnologiesResearch and Markets released a market analysis report projecting the global cell therapy market to reach $8.8 billion by 2027, growing at a compound annual growth rate of 5.4% during the forecast period, driven by rising adoption of regenerative medicine and introduction of novel platforms and technologies. Currently, FDA-approved commercial cell therapies remain limited, with LAVIV (Azficel-T) by Fibrocell Technologies having witnessed revenue decline in recent years, while companies like MaxCyte have established over 40 cellular therapy partnership programs. The Asia-Pacific region, particularly Japan, is anticipated to witness significant growth due to increasing patient awareness, lower treatment costs, and expanding research activities in regenerative medicine.PR NewswireBragar Eagel & Squire, P.C. is Investigating the Board of Directors of Fibrocell Science, Inc. (NASDAQ: FCSC) on Behalf of Fibrocell Shareholders and Encourages Fibrocell Investors to Contact the FirmBragar Eagel & Squire, P.C. is investigating the board of directors of Fibrocell Science, Inc. regarding a proposed $63.3 million merger with Castle Creek Pharmaceutical Holdings. The inquiry focuses on potential violations of federal securities laws and breaches of fiduciary duty concerning the fairness of the transaction process and share valuation.FierceBiotechFibrocell, Castle Creek ink rare disease gene therapy pacts worth up to $135MFibrocell has entered a licensing agreement with Castle Creek Pharma for its mid-stage gene therapy candidate FCX-007, aimed at treating recessive dystrophic epidermolysis bullosa (RDEB). Under the deal, Castle Creek will assume manufacturing and development costs through the FDA approval filing, providing Fibrocell with up to $135 million in potential milestone payments and profit shares. The partnership enables Fibrocell to advance its separate scleroderma program, FX-013, while Castle Creek prepares to initiate a phase 3 study for FCX-007 in the second quarter of this year.PR NewswireIntrexon Announces Third Quarter 2018 Financial ResultsIntrexon Corporation reported Q3 2018 financial results with GAAP revenues of $32.4 million, a 30% decrease year-over-year, and a net loss attributable to the company of $57.3 million including $38.7 million in non-cash charges, with Adjusted EBITDA of negative $28.9 million. The company highlighted commercial achievements across its portfolio including Okanagan Specialty Fruits' Arctic Apple harvest yielding ten times last year's production, EnviroFlight's phase one BSFL facility opening, and several clinical and technical milestones from subsidiaries including Precigen, Oxitec, ActoBio Therapeutics, and Fibrocell Science. CEO Randal J. Kirk stated the company is transitioning from science and technology to products and product candidates, with a focus on commercialization of transformative offerings.PR NewswireThis Morning's Technical Outlook on Generic Drugs Stocks -- Fibrocell Science, Galectin Therapeutics, Lannett, and MallinckrodtWallStEquities.com published a market commentary piece covering four generic drugs sector stocks: Fibrocell Science Inc., Galectin Therapeutics Inc., Lannett Co. Inc., and Mallinckrodt PLC, providing trading updates for April 17, 2018. Fibrocell Science shares declined 3.11% to $0.62 with an RSI of 50.95, while Galectin Therapeutics reported a 2017 net loss of $17.5 million with $3.1 million in cash. Lannett announced executive appointments (Grant Brock as VP operations and Alicia Evolga as VP of marketing), and Mallinckrodt disclosed board changes with Angus Russell succeeding Melvin Booth as non-executive chairman.